Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in ...

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...

Respiratory viruses can remain hidden in immune cells in the lungs long after the initial symptoms of an infection have ...

Rural women with COPD face rising mortality rates, while urban women and men see declines. A new study highlights the social ...

Symptoms and activity improved in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Study reveals that COVID-19 significantly increases the risk of chronic fatigue syndrome, with specific populations, such as ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...

On Sept 17, 2024, tobacco giant Philip Morris International (PMI) announced that it was selling Vectura at an enormous loss. Vectura, a pharmaceutical company that specialises in inhaled medicines for ...

as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. Specifically, the approval covers patients ...

The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...